Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-αvβ8 monoclonal antibody (Venn Therapeutics)
- Development stage
- Preclinical
- Lead developer
- Venn Therapeutics
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intraperitoneal, Intravenous, Subcutaneous
01
Overview
Venn Therapeutics is developing a program of monoclonal antibodies targeting the αvβ8 integrin for the treatment of solid tumors. The αvβ8 integrin is a key mediator in the activation of latent TGF-β (Transforming Growth Factor-beta) within the tumor microenvironment. By blocking this integrin, the antibodies are intended to inhibit TGF-β signaling, which is often exploited by tumors to suppress the immune system and promote growth. This therapeutic approach aims to restore anti-tumor immunity and reduce fibrosis within the tumor microenvironment. The program is currently in the preclinical stage of development.
- Other names
- Anti-αvβ8 monoclonal antibody programs
02
Targets
αVβ8 (Integrin alpha V beta 8)
Beyond the preview
Go deeper on anti-αvβ8 monoclonal antibody (Venn Therapeutics).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-αvβ8 monoclonal antibody (Venn Therapeutics).